2Pabst T, Mueller BU, Zhang P, et al. Dominant-negative mutations of CEBPA, encoding CCAAT/enhancer binding protein alpha (CEBPA), in acute myeloid leukemia. Nat Genet, 2001 ; 27 (3): 263-270.
3Frohling S, Schlenk RF, Stolze I, et al. CEBPA mutations in younger adults with acute myeloid leukemia and normal cytogenetics : prognostic relevance and analysis of cooperating mutations. J Clin Oncol, 2004; 22(4) : 624 -633.
4Preudhomme C, Sagot C, Boissel N, et al. Favorable prognostic significance of CEBPA mutations in patients with de novo acute myeloid leukemia: a study from the Acute Leukemia French Association (ALFA). Blood, 2002; 100(8): 2717-2723.
5Gombart AF, Hofmann WK, Kawano S, et al. Mutations in the gene encoding the transcription factor CCAAT/enhancer binding protein α in myelodysplastic syndromes and acute myeloid leukemias. Blood, 2002; 99(4): 1332- 1340.
6Lin LI, Chen CY, Lin DT, et al. Characterization of CEBPA mutations in acute myeloid leukemia: most patients with CEBPA mutations have biallelic mutations and show a distinct immunophenotype of the leukemic cells. Cllin Cancer Res, 2005; 11 (4) : 1372 - 1379.
8Mrozek K, Bloomfield CD. Chromosome Aberrations, Gene mutations and expression changes, and prognosis in adult acute myeloid leukemia. Hemalology Am Soc Hematol Educ Program, 2006 ; 169 - 177.
9Leroy H, Roumier C, Huyghe P, et al. CEBPA point mutations in hematological malignancies. Leukemia, 2005 ; 19 ( 3 ) : 329 - 334.
10Frohling S, Schlenk RF, Stolze I, et al. CEBPA Mutations in younger adults with acute myeloid leukemia and normal cytogenetics: prognostic relevance and analysis of cooperating mutations. J Clin Oncol, 2004; 22(4) : 624 -633.
